1. How Does Dshea Define Dietary Supplements and What Products Fall under Its Scope?
Under DSHEA, a dietary supplement is a product intended to supplement the diet that contains one or more of the following dietary ingredients: vitamins, minerals, herbs, amino acids, enzymes, probiotics, or other botanical substances. The statute also covers metabolites, constituents, extracts, and combinations of these ingredients. Products marketed as dietary supplements must be intended for ingestion and cannot be represented as a conventional food or as the sole item of a meal or diet.
DSHEA's definition is intentionally broad, which creates compliance complexity for healthcare professionals (HCPs) recommending these products to patients. An HCP should understand that the classification hinges on how a product is marketed and labeled, not its chemical composition alone. A substance identical in form to a drug may be treated as a dietary supplement if it is marketed with supplement-compliant claims and labeling. Conversely, if a manufacturer makes a disease claim (such as treats diabetes or cures hypertension), the product is automatically reclassified as a drug under FDA law, triggering stricter pre-market approval requirements and different regulatory oversight.
2. What Claims Can Manufacturers and Healthcare Professionals Lawfully Make about Dietary Supplements?
DSHEA permits three categories of permissible claims: structure-function claims, nutrient content claims, and qualified health claims. Structure-function claims describe how a nutrient or ingredient affects normal function or structure of the body (for example, supports joint health or promotes immune function). Nutrient content claims state the level of a nutrient in the product (such as high in vitamin C). Qualified health claims convey a relationship between a food component and a disease or health condition, but must be accompanied by qualifying language that reflects the level of scientific evidence supporting the claim.
Disease claims, by contrast, are prohibited for dietary supplements. An HCP must be cautious when discussing supplements with patients, because recommending a product while stating or implying it treats, prevents, mitigates, or cures a disease converts that product into a drug in the eyes of the FDA. Many HCPs inadvertently cross this line by saying this supplement cures your arthritis or take this to lower your cholesterol. The practical consequence is that a manufacturer who receives a report of such a claim may face FDA warning letters, product recalls, or enforcement litigation. HCPs should document their own education and training on permissible claim language and ensure that patient communications and written materials comply with DSHEA standards.
3. What Are the Substantiation and Safety Obligations Placed on Dietary Supplement Manufacturers?
DSHEA reversed the traditional regulatory burden: manufacturers, not the FDA, bear responsibility for ensuring that dietary supplements are safe before marketing. Manufacturers must have competent and reliable scientific evidence substantiating any claims made about their products. The FDA does not pre-approve dietary supplements before they enter the market, but it can take enforcement action if a product is adulterated (contaminated or improperly manufactured), misbranded (labeled falsely or misleadingly), or if claims lack adequate substantiation.
Manufacturers must also establish quality control procedures and register their facilities with the FDA. New dietary ingredient notifications are required if a supplement contains an ingredient not marketed in the United States before October 15, 1994. An HCP who recommends a supplement should inquire whether the manufacturer has conducted stability testing, microbiological testing, and identity verification of ingredients. Documentation of these quality measures can protect both the manufacturer and the HCP recommending the product. Many HCPs maintain records showing which supplements they have vetted for quality and substantiation as part of their professional due diligence.
How Does Fda Enforcement Work under Dshea?
The FDA enforces DSHEA through several mechanisms: warning letters to manufacturers citing specific violations, mandatory recall notifications, seizure of adulterated or misbranded products, and civil or criminal prosecution in federal court. When the FDA identifies a supplement making unauthorized disease claims or containing undisclosed contaminants, it typically issues a warning letter first, giving the manufacturer a period to correct the violation. If the manufacturer does not comply, the FDA may refer the matter to the Department of Justice for criminal prosecution or file a civil complaint seeking injunctive relief and product seizures.
HCPs should be aware that the FDA publishes enforcement actions and warning letters on its website, and an HCP's recommendation of a product subject to an active FDA enforcement action could expose the HCP to professional liability or regulatory scrutiny. Practitioners in New York and other states may face state licensing board complaints if they recommend supplements that are subsequently found to be adulterated, misbranded, or making unauthorized claims, particularly if the HCP's recommendation contributed to patient harm.
What Role Do New York Courts and State Agencies Play in Supplement Regulation?
While DSHEA is federal law, New York has concurrent authority over dietary supplement advertising and labeling under state consumer protection and health laws. The New York Department of Health and the New York Attorney General's Office can investigate complaints about misleading supplement marketing or contaminated products. An HCP recommending supplements in New York should be aware that state consumer fraud statutes prohibit deceptive advertising, and violation of those statutes can trigger civil penalties, injunctions, and restitution orders.
New York courts have upheld FDA determinations that a product is a drug rather than a dietary supplement when the marketing and labeling clearly communicate a disease claim. If an HCP is sued in state court for recommending a supplement that caused injury, the plaintiff may argue that the HCP breached a duty of care by failing to verify the product's safety profile, substantiation, or FDA compliance status. Maintaining documentation of the HCP's review of the supplement's quality, ingredients, and permissible claims is a practical defense against such claims.
4. What Should Healthcare Professionals Understand about Their Professional Obligations When Recommending Dietary Supplements?
HCPs occupy a unique position: they are not manufacturers, so they do not bear the same substantiation burden as a supplement company. However, HCPs have a professional duty to exercise reasonable care in recommending products to patients. This means verifying that a supplement is manufactured by a reputable company, that the product's ingredients match the label, that the HCP's own statements about the product comply with DSHEA's claim restrictions, and that the recommendation is appropriate for the patient's health status and medications.
An HCP should maintain records documenting why a particular supplement was recommended, what claims were discussed with the patient, and what patient education materials were provided. If a supplement is later recalled or subject to FDA enforcement action, the HCP's contemporaneous documentation protects against allegations of negligence or professional misconduct. HCPs should also stay informed about FDA warning letters and recalls by subscribing to FDA updates or consulting resources maintained by professional organizations. Many HCPs consult with workplace safety and health compliance specialists or regulatory counsel when developing institutional policies on supplement recommendations.
5. What Practical Steps Can Healthcare Professionals Take to Ensure Dshea Compliance in Clinical Practice?
HCPs should implement a vetting process for any supplement they recommend or sell in their practice. This process should include verifying that the manufacturer is FDA-registered, checking the FDA's enforcement action database and recall lists, confirming that the supplement's label matches the product's actual contents, and ensuring that any written materials or verbal statements made about the supplement comply with DSHEA's claim restrictions. HCPs should also document patient education on the difference between dietary supplements and drugs, including the fact that supplements are not subject to pre-market FDA approval.
Institutional policies governing
15 May, 2026
